{"id":27,"date":"2023-09-06T08:26:09","date_gmt":"2023-09-06T08:26:09","guid":{"rendered":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo_wp\/?page_id=27"},"modified":"2023-11-06T07:49:08","modified_gmt":"2023-11-06T07:49:08","slug":"achievement","status":"publish","type":"page","link":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/achievement","title":{"rendered":"\u7814\u7a76\u696d\u7e3e"},"content":{"rendered":"

\u5b66\u4f1a\u767a\u8868<\/h1>\n

Phase\u2160<\/span>\/<\/span>\u2161<\/span> trial of glif for taxane\/platinum-resistant endometrial canver<\/b><\/b><\/font><\/span><\/span><\/span><\/span><\/span><\/span> <\/span><\/span><\/span><\/span><\/span><\/h3>\n

<\/span><\/span><\/span><\/span><\/span>Nakagawa, S.   Ueda, Y.   Matsuzaki, S.  
\n Takata, T.   Kobayashi, E.   Yoshino, K.  
\n Kimura, T.
\n 19th International Meeting of the European Society of Gynaecological Oncology
\n (ESGO 2015) 2015<\/p>\n

\u30af\u30ea\u30cb\u30ab\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3\u3000CCRT\u306e\u6b74\u53f2\u3068\u65b0\u305f\u306a\u6311\u6226>
\n \u5b50\u5bae\u9838\u764c\u306b\u5bfe\u3059\u308b\u30d1\u30af\u30ea\u30bf\u30ad\u30bb\u30eb\u30fb\u30ab\u30eb\u30dc\u30d7\u30e9\u30c1\u30f3\u3092\u7528\u3044\u305f\u540c\u6642\u5316\u5b66\u653e\u5c04\u7dda\u6cbb\u7642<\/b><\/span><\/span><\/span><\/span><\/span><\/h3>\n

<\/span><\/span><\/span><\/span><\/span>\u99ac\u6df5\u8aa0\u58eb.
\n \u7b2c12\u56de \u5a66\u4eba\u79d1\u304c\u3093\u4f1a\u8b70 2015<\/p>\n

\u5b50\u5bae\u9838\u764c\u306b\u5bfe\u3059\u308b\u30d1\u30af\u30ea\u30bf\u30ad\u30bb\u30eb\u30fb\u30ab\u30eb\u30dc\u30d7\u30e9\u30c1\u30f3\u3092\u7528\u3044\u305f\u540c\u6642\u5316\u5b66\u653e\u5c04\u7dda\u6cbb\u7642<\/span><\/span><\/span><\/span><\/span><\/h3>\n

<\/span><\/span><\/span><\/span><\/span>\u99ac\u6df5\u8aa0\u58eb.  \u9ed2\u7530\u6d69\u6b63.  \u78ef\u6a4b\u6587\u660e.  \u7b39\u91ce\u667a\u4e4b.  \u5c0f\u6797\u6804\u4ec1.  \u6728\u6751\u654f\u5553. 
\n \u4e0a\u7530\u3000\u8c4a.  \u6fa4\u7530\u5065\u4e8c\u90ce.  \u5409\u91ce\u3000\u6f54. 
\n \u7b52\u4e95\u5efa\u7d00.  \u85e4\u7530\u5f81\u5df3.  \u6728\u6751\u3000\u6b63.
\n \u7b2c56\u56de\u65e5\u672c\u5a66\u4eba\u79d1\u816b\u760d\u5b66\u4f1a 2014<\/p>\n

\u30bf\u30ad\u30b5\u30f3\u30fb\u30d7\u30e9\u30c1\u30ca\u62b5\u6297\u5b50\u5bae\u4f53\u764c\u306b\u5bfe\u3059\u308bGLIF\u7642\u6cd5\u306e\u6709\u52b9\u6027\u3068\u6709\u5bb3\u4e8b\u8c61\u306e\u691c\u8a0e<\/span><\/span><\/span><\/span><\/span><\/h3>\n

<\/span><\/span><\/span><\/span><\/span>\u4e2d\u5ddd\u3000\u6167.  \u4e0a\u7530\u3000\u8c4a.  \u5e73\u677e\u5b8f\u7950.  \u6e05\u539f\u88d5\u7f8e\u5b50.  \u68ee\u672c\u6676\u5b50.  \u677e\u5d0e\u614e\u54c9. 
\n \u9ad8\u7530\u53cb\u7f8e.  \u5c0f\u6797\u6804\u4ec1.  \u6728\u6751\u654f\u5553. 
\n \u78ef\u90e8\u3000\u6676.  \u99ac\u6df5\u8aa0\u58eb.  \u6fa4\u7530\u5065\u4e8c\u90ce.  \u5409\u91ce\u3000\u6f54.  \u85e4\u7530\u5f81\u5df3.  \u7b52\u4e95\u5efa\u7d00. 
\n \u6728\u6751\u3000\u6b63.
\n \u7b2c56\u56de\u65e5\u672c\u5a66\u4eba\u79d1\u816b\u760d\u5b66\u4f1a 2014<\/p>\n

\u5e83\u6c4e\u5b50\u5bae\u5168\u6458\u51fa\u5f8c\u306e\u4e2d\u30ea\u30b9\u30af\u7fa4\u30fb\u9ad8\u30ea\u30b9\u30af\u7fa4\u306b\u5bfe\u3059\u308b\u8853\u5f8c\u540c\u6642\u5316\u5b66\u653e\u5c04\u7dda\u7642\u6cd5\u306e
\n \u6709\u7528\u6027\u306e\u691c\u8a0e<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n

<\/span><\/span><\/span><\/span><\/span>\u9ed2\u7530\u6d69\u6b63.  \u5ca1\u6fa4\u7f8e\u4f73.  \u99ac\u6df5\u8aa0\u58eb.  \u7b39\u91ce\u667a\u4e4b.  \u9ad8\u6a4b\u826f\u5b50.  \u6cb3\u91ce\u307e\u3072\u308b. 
\n \u677e\u672c\u6709\u91cc.  \u592a\u7530\u884c\u4fe1.  \u4e0a\u6d66\u7965\u53f8. 
\n \u6fa4\u7530\u5065\u4e8c\u90ce.  \u6728\u6751\u3000\u6b63.
\n \u7b2c56\u56de\u65e5\u672c\u5a66\u4eba\u79d1\u816b\u760d\u5b66\u4f1a 2014<\/p>\n

\u30d7\u30e9\u30c1\u30ca\u62b5\u6297\u6027\u306e\u518d\u767a\u5b50\u5bae\u4f53\u764c\u306b\u5bfe\u3057\u3066GLIF<\/font>\u7642\u6cd5\u304c\u8457\u52b9\u3057\u305f1<\/font>\u4f8b<\/span><\/span><\/span><\/span><\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n

\u4e2d\u5ddd\u3000\u6167.  \u4e0a\u7530\u3000\u8c4a.  \u6728\u6751\u654f\u5553.  \u5c0f\u6797\u6804\u4ec1.  \u78ef\u90e8\u3000\u6676.  \u99ac\u6df5\u8aa0\u58eb. 
\n \u6fa4\u7530\u5065\u4e8c\u90ce.  \u5409\u91ce\u3000\u6f54.  \u85e4\u7530\u5f81\u5df3. 
\n \u7b52\u4e95\u5efa\u7d00.  \u6728\u6751\u3000\u6b63.
\n \u7b2c130\u56de\u8fd1\u757f\u7523\u79d1\u5a66\u4eba\u79d1\u5b66\u4f1a 2014<\/p>\n

\u30d7\u30e9\u30c1\u30ca\u62b5\u6297\u6027\u518d\u767a\u5375\u5de3\u764c\u306b\u5bfe\u3059\u308bCPT-11+Gemcitabine<\/font> \u4f75\u7528\u5316\u5b66\u7642\u6cd5
\n -\u7b2cI\/II \u76f8\u8a66\u9a13<\/b><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n

\u5409\u91ce\u3000\u6f54.
\n CPT\uff0d11\u5b66\u8853\u8b1b\u6f14\u4f1a\uff0d\u5a66\u4eba\u79d1\u9818\u57df\u306b\u304a\u3051\u308b\u764c\u5316\u5b66\u7642\u6cd5\u306e\u5f79\u5272\uff0d 2014<\/p>\n

\u2162\/\u2163\u671f\u5375\u5de3\u304c\u3093\u5b8c\u5168\u5bdb\u89e3\u306b\u5bfe\u3059\u308bWT1<\/font>\u30da\u30d7\u30c1\u30c9\u30ef\u30af\u30c1\u30f3\u514d\u75ab\u7642\u6cd5\u306e\u7b2c\u2161\u76f8\u81e8\u5e8a\u8a66\u9a13<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>\u897f\u7530\u7d14\u5e78.  \u5409\u91ce\u3000\u6f54.  \u4e0a\u7530\u3000\u8c4a.  \u5ca1\u3000\u82b3\u5f18.  \u68ee\u7530\u667a\u8996.  \u6728\u6751\u3000\u6b63. 
\n \u6749\u5c71\u6cbb\u592b.
\n \u7b2c17\u56deWT1\u30da\u30d7\u30c1\u30c9\u764c\u514d\u75ab\u7642\u6cd5\u7814\u7a76\u4f1a 2014<\/p>\n<\/p><\/div>\n

\u30bf\u30ad\u30b5\u30f3\u88fd\u5264\u30fb\u30d7\u30e9\u30c1\u30ca\u88fd\u5264\u62b5\u6297\u6027\u5b50\u5bae\u4f53\u764c\u306b\u5bfe\u3059\u308bGLIF<\/font>\u7642\u6cd5\u306b\u95a2\u3059\u308b
\n \u7b2c1<\/font>\u76f8\u81e8\u5e8a\u8a66\u9a13\uff08GOGO-EM2<\/font>\uff09<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>\u4e2d\u5ddd\u3000\u6167.  \u4e0a\u7530\u3000\u8c4a.  \u677e\u5d0e\u614e\u54c9.  \u5c0f\u6797\u6804\u4ec1.  \u6728\u6751\u654f\u5553.  \u78ef\u90e8\u3000\u6676.  \u99ac\u6df5\u8aa0\u58eb.  \u6fa4\u7530\u5065\u4e8c\u90ce.  \u5409\u91ce\u3000\u6f54. 
\n \u85e4\u7530\u5f81\u5df3.  \u7b52\u4e95\u5efa\u7d00.  \u6728\u6751\u3000\u6b63.  \u5c71\u5d5c\u6b63\u4eba.  \u897f\u5c3e\u5e78\u6d69.  \u5c71\u672c\u654f\u4e5f. 
\n \u52a0\u85e4\u5b97\u5bdb.  \u5fd7\u5c90\u4fdd\u5f66.  \u8db3\u7acb\u548c\u7e41.  \u5c0f\u5ddd\u6674\u757f
\n \u7b2c54\u56de\u65e5\u672c\u5a66\u4eba\u79d1\u816b\u760d\u5b66\u4f1a 2013<\/p>\n<\/p><\/div>\n

Phase 1 study of
\n combination chemotherapy with irinotecan and gemicitabine for taxane\/platinum
\n resistant ovarian, fallopian tube, or primary petoneal cancer<\/b><\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>Yoshino, K.   Kamiura, S.   Ogawa, H.   Tokuhira,
\n A.   Takemura, M.   Sawada, K.   Ueda, Y.  
\n Mabuchi, S.   Fujita, M.   Tsutsui, T.  
\n Kimura, T.
\n The 48th Annual Meeting of the American Society of Clinical Oncology 2013<\/p>\n

\u6cbb\u7642\u62b5\u6297\u6027\u306e\u5a66\u4eba\u79d1\u60aa\u6027\u816b\u760d\u306b\u5bfe\u3059\u308bWT1<\/font>\u30da\u30d7\u30c1\u30c9\u30ef\u30af\u30c1\u30f3\u7642\u6cd5<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>\u68ee\u672c\u6676\u5b50.  \u4e0a\u7530\u3000\u8c4a.  \u5bae\u6b66\u3000\u5d07.  \u5409\u91ce\u3000\u6f54.  \u85e4\u7530\u5f81\u5df3.  \u7b52\u4e95\u5efa\u7d00. 
\n \u698e\u672c\u9686\u4e4b.  \u6728\u6751\u3000\u6b63.
\n \u7b2c16\u56deWT1\u30da\u30d7\u30c1\u30c9\u764c\u514d\u75ab\u7642\u6cd5\u7814\u7a76\u4f1a 2013<\/p>\n<\/p><\/div>\n<\/p><\/div>\n

Salvage chemotherapy
\n using gemcitabine for taxane\/platinum-resistant recurrent ovarian cancer: A
\n single institutional experience<\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>Yoshino, K.   Hiramatsu, K.   Enomoto, T.  
\n Fujita, M.   Ueda, Y.   Toshihiro Kimura  
\n Kobayashi, E.   Kiyohara, Y.   Tsutsui, T.  Kimura,
\n T.
\n 14th Biennial Meeting of the International Gynecologic Cancer Society 2012<\/span>\n <\/p>\n

\u6cbb\u7642\u62b5\u6297\u6027\u5a66\u4eba\u79d1\u60aa\u6027\u816b\u760d\u306b\u5bfe\u3059\u308bWTI<\/font>\u30da\u30d7\u30c1\u30c9\u30ef\u30af\u30c1\u30f3\u7b2c\u2161\u76f8\u81e8\u5e8a\u8a66\u9a13<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>\u68ee\u672c\u6676\u5b50.  \u698e\u672c\u9686\u4e4b.  \u4e0a\u7530\u3000\u8c4a.  \u5bae\u6b66\u3000\u5d07.  \u5409\u91ce\u3000\u6f54.  \u85e4\u7530\u5f81\u5df3. 
\n \u7b52\u4e95\u5efa\u7d00.  \u767d\u65b9\u4fca\u7ae0.  \u897f\u7530\u7d14\u5e78.  \u5ca1\u3000\u82b3\u5f18.  \u6749\u5c71\u6cbb\u592b.  \u6728\u6751\u3000\u6b63.
\n \u7b2c64\u56de\u65e5\u672c\u7523\u79d1\u5a66\u4eba\u79d1\u5b66\u4f1a 2012
\n \u68ee\u672c\u6676\u5b50.  \u4e0a\u7530\u3000\u8c4a.  \u5bae\u6b66\u3000\u5d07.  \u698e\u672c\u9686\u4e4b.  \u5ca1\u3000\u82b3\u5f18.  \u897f\u7530\u7d14\u5e78. 
\n \u576a\u4e95\u662d\u535a.  \u767d\u65b9\u4fca\u7ae0.  \u5c3e\u8def\u7950\u4ecb.  \u68ee\u7530\u667a\u8996.  \u5742\u672c\u7d14\u4e00.  \u6749\u5c71\u6cbb\u592b. 
\n \u6728\u6751\u3000\u6b63.
\n \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a 2012<\/p>\n<\/p><\/div>\n<\/p><\/div>\n


\n \u5b50\u5bae\u4f53\u764c\u306b\u5bfe\u3059\u308b<\/span><\/span><\/span><\/span>TEC<\/span><\/font>\u7642\u6cd5TEC<\/font>(paclitaxel+epirubicin+carboplatin)<\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/span>\u306e\u6cbb\u7642\u6210\u7e3e<\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span>\u9ad8\u7530\u53cb\u7f8e.  \u4e0a\u7530\u3000\u8c4a.  \u4e09\u5b85\u8cb4\u4ec1.  \u5bae\u6b66\u3000\u5d07.  <\/span>\u85e4\u7530\u5f81\u5df3.  \u5409\u91ce\u3000\u6f54.  \u5ca1\u6fa4\u7f8e\u4f73.  \u7b52\u4e95\u5efa\u898f.  \u68ee\u91cd\u5065\u4e00\u90ce. 
\n \u5c71\u5d5c\u6b63\u4eba.  \u897f\u5d0e\u5b5d\u9053.  \u9577\u677e\u6b63\u7ae0.  \u4f0a\u85e4\u516c\u5f66.  \u6d45\u7530\u660c\u5b8f.  \u837b\u7530\u548c\u79c0. 
\n \u8107\u672c\u662d\u61b2.  \u5c71\u672c\u654f\u4e5f.  \u897f\u5c3e\u5e78\u6d69.  \u698e\u672c\u9686\u4e4b
\n \u7b2c50<\/span>\u56de\u65e5\u672c\u5a66\u4eba\u79d1\u816b\u760d\u5b66\u4f1a 2011<\/span><\/span>\n <\/p>\n

CPT-11\/Docetaxel<\/font>\u4f75\u7528\u7642\u6cd5\u3092\u7528\u3044\u305f\u5375\u5de3\u660e\u7d30\u80de\u817a\u764c\u3001\u7c98\u6db2\u6027\u817a\u764c\u306b\u5bfe\u3059\u308b
\n \u8853\u5f8c\u5316\u5b66\u7642\u6cd5\u306e\u6709\u7528\u6027\u306e\u691c\u8a0e<\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span>\u5bae\u6b66\u3000\u5d07.  \u4e0a\u7530\u3000\u8c4a.  <\/span>\u677e\u5d0e\u614e\u54c9.  \u9023\u3000\u7f8e\u7a42.  \u9ad8\u7530\u53cb\u7f8e.  \u5b87\u57a3\u5f18\u7f8e.  \u91d1\u3000\u96c5\u5b50.  \u85e4\u7530\u5f81\u5df3. 
\n \u698e\u672c\u9686\u4e4b. 
\n \u6728\u6751\u6b63.  \u5c71\u5d5c\u6b63\u4eba.  \u9577\u677e\u6b63\u7ae0
\n \u7b2c61\u56de\u65e5\u672c\u7523\u5a66\u4eba\u79d1\u5b66\u4f1a\u5b66\u8853\u8b1b\u6f14\u4f1a 2009<\/span><\/p>\n<\/p><\/div>\n

Paclitaxel\/carboplatin<\/font>\u4e0d\u5fdc\u30fb\u62b5\u6297\u6027\u5375\u5de3\u764c\u306b\u5bfe\u3059\u308birinotecan\/docetaxel<\/font><\/span><\/span>\u4f75\u7528\u7642\u6cd5\u306e
\n phase \u2161 study.<\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

\u698e\u672c\u9686\u4e4b<\/span>
\n \u7b2c45\u56de\u65e5\u672c\u5a66\u4eba\u79d1\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a 2008
\n <\/o:p>
\n <\/span>\n <\/p>\n<\/p><\/div>\n

Management of Clear Cell Carcinoma and Mucinous Carcinoma of the Ovary\uff1aMulti-Institutional
\n Study in Osaka, Japan\u3000International Symposium4 Recent Advances in Gynecologic
\n Oncology.<\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/font><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span>Enomoto T.
\n <\/span><\/span><\/span>
\n <\/o:p>
\n <\/o:p>
\n <\/span><\/span>\u7b2c59\u56de\u65e5\u672c\u7523\u5a66\u4eba\u79d1\u5b66\u4f1a 2007<\/span>\n <\/p>\n<\/p><\/div>\n

A phase II study of combination CPT-11 and docetaxel patients with ovarian
\n carcinoma refractory or resistant to combination paclitaxel and carboplatin.<\/font><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>Enomoto T,\u3000Yoshino K,\u3000Yamasaki M,\u3000Nishio Y,\u3000Wakimoto A,\u3000Miyake T,\u3000Fujiwara K,\u3000
\n Takemura M,\u3000Ito K,\u3000Gynecologic Oncology Group of Osaka.
\n <\/span>11th Biennial International Gynecologic Cancer Society Meeting 2006
\n <\/o:p>
\n <\/span><\/span>\n <\/p>\n<\/p><\/div>\n

Management of clear cell carcinoma and mucinous carcinoma of the ovary:
\n Multi-institutional prospective study in Osaka, Japan (GOGO-Ov1, Ov2, Ov3).<\/font><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span>Enomoto T.
\n <\/span>Asian and Oceanic Congress of Obstetrics \uff06 Gynecology 2005
\n <\/o:p>
\n <\/span><\/span>\n <\/p>\n<\/p><\/div>\n

The second line chemotherapy for the ovarian carcinoma after the first
\n line chemotherapy with the combination of paclitaxel and carboplatin.<\/font><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>Nakashima R,\u3000Enomoto T,\u3000Yamasaki M,\u3000Matsuzaki N,\u3000Ohtsuki Y,\u3000Yamamoto T,\u3000Ikegami
\n H,
\n Ogawa H,\u3000Wakimoto A,\u3000Kamiura S,\u3000Mizutani T,\u3000Yoshino K,\u3000Kuragaki C,\u3000Fujita
\n M,\u3000Murata Y.
\n <\/span>10th Biennial International Gynecologic Cancer Society Meeting 2004<\/span>\n <\/p>\n<\/p><\/div>\n

\u521d\u56de<\/span><\/span><\/span><\/span><\/span><\/font>Paclitaxel\/carboplatin<\/span><\/font><\/font><\/span><\/span><\/span><\/span><\/span><\/font>\u6cbb\u7642\u5f8c\u518d\u767a\u3057\u305f\u4e0a\u76ae\u6027\u60aa\u6027\u5375\u5de3\u816b\u760d\u306b\u5bfe\u3059\u308b2nd line<\/font> chemotherapy<\/font><\/span><\/span><\/span><\/span><\/span><\/span>
\n <\/o:p>
\n <\/span><\/span><\/span><\/span><\/font><\/h3>\n
<\/span><\/p>\n

<\/span>\u698e\u672c\u9686\u4e4b.  \u4e2d\u5d8c\u7adc\u4e00.  \u5c71\u5d5c\u6b63\u4eba.  \u5009\u57a3\u5343\u6075.  \u677e\u5d0e\u3000\u6607.  \u5927\u69fb\u82b3\u90ce. 
\n \u6749\u7530\u9577\u654f.  \u6c60\u4e0a\u535a\u96c5.  \u5c0f\u5ddd\u6674\u757f. 
\n \u8107\u672c\u662d\u61b2<\/span>.  \u677e\u5d0e\u3000\u6607.  \u5927\u69fb\u82b3\u6717.  \u6749\u7530\u9577\u654f.  \u6c60\u4e0a\u535a\u96c5.  \u5c0f\u5ddd\u6674\u5e7e.  \u8107\u672c\u662d\u61b2.  \u4f50\u6cbb\u6587\u9686.  \u5c71\u7530\u9686\u5b50. 
\n \u6c34\u8c37\u9686\u6d0b.  \u897f\u5d0e\u5b5d\u9053.  \u4e80\u7530\u3000\u9686.  \u5149\u7530\u4fe1\u660e.  \u9577\u677e\u6b63\u7ae0.  \u52a0\u85e4\u6cbb\u5b50.  \u6771\u3000\u5343\u5c0b.  \u4f0a\u85e4\u516c\u5f66.  \u5b89\u85dd\u5fe0\u7be4. 
\n \u4e0a\u6d66\u7965\u53f8.  \u85e4\u7530\u5f81\u5df3.  \u7530\u5742\u6176\u4e00.  \u6751\u7530\u96c4\u4e8c<\/span>.
\n \u7b2c41\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a 2003
\n <\/o:p>
\n <\/span>\n <\/p>\n<\/p><\/div>\n

\u521d\u56dePaclitaxel\/carboplatin<\/font><\/span>\u6cbb\u7642\u5f8c\u518d\u767a\u3057\u305f\u4e0a\u76ae\u6027\u60aa\u6027\u5375\u5de3\u816b\u760d\u306b\u5bfe\u3059\u308b\u5316\u5b66\u7642\u6cd5<\/span><\/span><\/span><\/span><\/span><\/font><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span>\u698e\u672c\u9686\u4e4b.  \u4e2d\u5d8c\u7adc\u4e00.  \u5c71\u5d5c\u6b63\u4eba.  \u5009\u57a3\u5343\u6075.  \u677e\u5d0e\u3000\u6607.  \u5927\u69fb\u82b3\u6717. 
\n \u6749\u7530\u9577\u654f.  \u6c60\u4e0a\u535a\u96c5.  \u5c0f\u5ddd\u6674\u5e7e. 
\n \u8107\u672c\u662d\u61b2.  \u4f50\u6cbb\u6587\u9686.  \u5c71\u7530\u9686\u5b50.  \u6c34\u8c37\u9686\u6d0b.  \u897f\u5d0e\u5b5d\u9053.  \u4e80\u7530\u3000\u9686. 
\n \u5149\u7530\u4fe1\u660e.  \u9577\u677e\u6b63\u7ae0.  \u52a0\u85e4\u6cbb\u5b50. 
\n \u6771\u3000\u5343\u5c0b.  \u4f0a\u85e4\u516c\u5f66.  \u5b89\u85dd\u5fe0\u7be4.  \u4e0a\u6d66\u7965\u53f8.  \u85e4\u7530\u5f81\u5df3.  \u7530\u5742\u6176\u4e00. 
\n \u6751\u7530\u96c4\u4e8c<\/span>.
\n \u7b2c109\u56de\u8fd1\u757f\u7523\u79d1\u5a66\u4eba\u79d1\u5b66\u4f1a 2003
\n <\/o:p>
\n <\/span>\n <\/p>\n<\/p><\/div>\n

Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to
\n combination chemotherapy with paclitaxel and carboplatin.<\/font><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span>Enomoto T,\u3000Kuragaki C,\u3000Yamasaki M,\u3000Sugita N,\u3000Otsuki Y,\u3000Ikegami H,\u3000Matsuzaki N,\u3000
\n Yamada T,\u3000Wakimoto A,\u3000Murata Y,\u3000Osaka GOGO.
\n <\/span>39<\/span>th Annual Meeting of the American Society of Clinical Oncology 2003
\n <\/o:p>
\n <\/span><\/span>\n <\/p>\n<\/p><\/div>\n

\n

\u9032\u884c\u307e\u305f\u306f\u518d\u767a\u5b50\u5bae\u4f53\u764c\u306b\u5bfe\u3059\u308bPaclitaxel+Epirubicin+CBDCA<\/span><\/font>\u4f75\u7528\u7642\u6cd5<\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span>\u4e2d\u5d8c\u7adc\u4e00.  \u698e\u672c\u9686\u4e4b.  \u85e4\u7530\u5f81\u5df3.  \u4e0a\u7530\u3000\u8c4a.  \u91d1\u5c3e\u7950\u4e4b.  \u4e0a\u91ce\u88d5\u5b50. 
\n \u5bae\u6b66\u3000\u5d07.  \u5409\u5d0e\u9054\u90ce.  \u5009\u57a3\u5343\u6075. 
\n \u6751\u7530\u96c4\u4e8c.  \u5c71\u5d5c\u6b63\u4eba.  \u677e\u5d0e\u3000\u6607.  \u4e80\u7530\u3000\u9686.  \u5c0f\u5ddd\u6674\u5e7e.<\/span>
\n \u7b2c40<\/span>\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a 2002
\n <\/o:p>
\n <\/span><\/span><\/p>\n<\/p><\/div>\n

<\/div>\n<\/p><\/div>\n
\n

\u9032\u884c\u307e\u305f\u306f\u518d\u767a\u5b50\u5bae\u4f53\u764c\u306b\u5bfe\u3059\u308bPaclitaxel+Epirubicin+CBDCA<\/span><\/font>\u4f75\u7528\u7642\u6cd5<\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span>\u4e0a\u7530\u3000\u8c4a.  \u698e\u672c\u9686\u4e4b.  \u4e2d\u5d8c\u7adc\u4e00.  \u6751\u7530\u96c4\u4e8c.
\n \u5927\u962a\u5927\u5b66\u533b\u5b66\u90e8\u7523\u5a66\u4eba\u79d1\u304a\u3088\u3073\u95a2\u9023\u75c5\u9662\u7523\u5a66\u4eba\u79d1\u764c\u6cbb\u7642\u7814\u7a76\u4f1a<\/span> 2002
\n <\/o:p>
\n <\/span><\/span>\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

Paclitaxel, epirubicin and carboplatin in advanced or recurrent carcinoma
\n of the endometrium<\/font>
\n <\/o:p>
\n <\/font><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span>Nakashima R,  <\/span>Nakamura T, Ueda Y, Enomoto T, Murata Y
\n <\/o:p>
\n <\/span>
\n 9th Biennial Meeting of the International Gynecologic Cancer Society 2002
\n <\/o:p>
\n <\/span>\n <\/p>\n<\/p><\/div>\n

\u4e0a\u76ae\u6027\u60aa\u6027\u5375\u5de3\u816b\u760d\u306b\u5bfe\u3059\u308bTC\uff08paclitaxel+CBDCA\uff09<\/font>\u7642\u6cd5\u306e\u7b2c\u4e8c\u76f8\u8a66\u9a13<\/span><\/h3>\n
\u698e\u672c\u9686\u4e4b<\/span>.
\n \u7b2c39<\/span>\u56de\u65e5\u672c\u764c\u6cbb\u7642\u5b66\u4f1a <\/span>2001
\n <\/o:p>
\n <\/span><\/span><\/span><\/p><\/div>\n

\u4e0a\u76ae\u6027\u60aa\u6027\u5375\u5de3\u816b\u760d\u306b\u5bfe\u3059\u308bTC\uff08Paclitaxel+CBDCA\uff09<\/font>\u7642\u6cd5\u306e\u7b2c\u4e8c\u76f8\u8a66\u9a13<\/span><\/h3>\n
<\/span><\/p>\n

GOGO
\n (Gynecologic Oncology Group of Osaka) (<\/span>\u5927\u962a\u5927\u4ed633<\/span>\u6a5f\u95a2\u3000\u8cac\u4efb\u8005: <\/span>\u6751\u7530\u96c4\u4e8c\uff09\u698e\u672c\u9686\u4e4b.
\n <\/o:p>
\n <\/span><\/span>
\n \u7b2c53<\/span>\u56de\u65e5\u672c\u7523\u79d1\u5a66\u4eba\u79d1\u5b66\u4f1a 2001<\/span><\/span>\n <\/p>\n<\/p><\/div>\n

\u9032\u884c\u307e\u305f\u306f\u518d\u767a\u5b50\u5bae\u4f53\u764c\u306b\u5bfe\u3059\u308b<\/font>Taxol+Epirubicin+CBDCA<\/font>\u4f75\u7528\u7642\u6cd5<\/span><\/h3>\n
\u85e4\u7530\u5f81\u5df3. <\/span>\u698e\u672c\u9686\u4e4b. <\/span>\u4e2d\u6751\u9686\u6587. <\/span>\u5009\u57a3\u5343\u6075. <\/span>\u5009\u667a\u535a\u4e45. <\/span>\u897f\u5d0e\u5b5d\u9053. <\/span>\u5c0f\u5009\u6f64\u5b50. <\/span>\u677e\u5d0e\u3000\u6607. <\/span>\u5c71\u5d5c\u6b63\u4eba. <\/span>\u6751\u7530\u96c4\u4e8c
\n <\/o:p>
\n <\/span><\/span>.
\n \u7b2c12<\/span>\u56de\u65e5\u672c\u5a66\u4eba\u79d1\u60aa\u6027\u816b\u760d\u5316\u5b66\u7642\u6cd5\u5b66\u4f1a <\/span>1999
\n <\/o:p>
\n <\/span><\/span><\/div>\n

\n <\/p>\n<\/p><\/div>\n<\/p><\/div>\n

\n

\u8ad6\u6587<\/h1>\n

A phase I\/II study of GLIF combination chemotherapy for taxane\/platinum-refractory\/resistant endometrial cancer (GOGO-EM2)<\/font><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

Tanaka, Y. Ueda, Y. Nakagawa, S. Matsuzaki, S. Kobayashi, E. Shiki, Y.
\n Nishio, Y. Takemura, M. Yamamoto, T. Sawada, K. Tomimatsu, T. Yoshino,
\n K. Kimura, T.
\n Cancer Chemother Pharmacol, 82:585-592, 2018 Oct.<\/p>\n<\/p><\/div>\n

<\/span><\/span><\/span><\/span><\/span><\/p>\n

Combination chemotherapy with irinotecan and gemcitabine for taxane\/platinum-resistant\/refractory ovarian and primary peritoneal cancer: A multicenter phase I\/II trial (GOGO-Ov 6)<\/font><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

Yoshino, K. Kamiura, S. Yokoi, T. Nakae, R. Fujita, M. Takemura, M. Adachi,
\n K. Wakimoto, A. Nishizaki, T. Shiki, Y. Tsutsui, T. Kanda, Y. Kobayashi,
\n E. Hashimoto, K. Mabuchi, S. Ueda, Y. Sawada, K. Tomimatsu, T. Kimura,
\n T.
\n Cancer Chemother Pharmacol, 80:1239-1247, 2017 Dec.<\/p>\n

<\/p>\n

Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB\/IVA cervical cancer patients<\/font><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

Mabuchi, S. Isohashi, F. Okazawa, M. Kitada, F. Maruoka, S. Ogawa, K. Kimura,
\n T.
\n J Gynecol Oncol<\/span>, 28:e15, 2017 Jan.<\/p>\n<\/p><\/div>\n

<\/p>\n

A phase II study of
\n postoperative concurrent carboplatin and paclitaxel combined with
\n intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy
\n in surgically treated cervical cancer patients with positive pelvic lymph nodes<\/font><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

Mabuchi, S.  Isohashi, F.  Yokoi, T.  Takemura, M. 
\n Yoshino, K.  Shiki, Y.  Ito, K.  Enomoto, T.  Ogawa,
\n K.  Kimura, T.
\n Gynecol Oncoll,  141:240-246,  2016 May.<\/p>\n<\/p><\/div>\n

WT1 peptide
\n immunotherapy for gynecologic malignancies resistant to conventional therapies:
\n a phase II trial<\/font><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

Miyatake, T.   Ueda, Y.   Morimoto, A.  
\n Enomoto, T.   Nishida, S.   Shirakata, T.  
\n Oka, Y.   Tsuboi, A.   Oji, Y.   Hosen, N.  
\n Nakatsuka, S.   Morita, S.   Sakamoto, J.  
\n Sugiyama, H.   Kimura, T.
\n J Cancer Res Clin Oncol,  139:457-463,  2013 Mar.<\/p>\n<\/p><\/div>\n

A phase I study of
\n concurrent weekly carboplatin and paclitaxel combined with intensity-modulated
\n pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer
\n patients with positive pelvic lymph nodes<\/font><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

Mabuchi, S.   Takahashi, R.   Isohashi, F.  
\n Yokoi, T.   Ito, K.   Tsutui, T.   Ogata,
\n T.   Yoshioka, Y.   Ogawa, K.   Kimura, T.
\n Int J Gynecol Cancer,  23:1279-1286,  2013 Sep.<\/p>\n<\/p><\/div>\n

A phase II study of
\n combination chemotherapy using docetaxel and irinotecan for TC-refractory or
\n TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or
\n mucinous ovarian carcinomas (GOGO-OV3 Study)<\/font><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

Ueda, Y.   Miyatake, T.   Nagamatsu, M.  
\n Yamasaki, M.   Nishio, Y.   Yoshino, K.  
\n Fujita, M.   Tsutsui, T.   Enomoto, T.  
\n Kimura, T.
\n Eur J Obstet Gynecol Reprod Biol,  170:259-263,  2013 Sep.<\/p>\n<\/p><\/div>\n

Salvage Chemotherapy Using Gemcitabine for Taxane\/Platinum-resistant Recurrent
\n Ovarian Cancer: A Single Institutional Experience<\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/font><\/span><\/h3>\n
<\/span><\/p>\n

<\/span>Yoshino, K.   Hiramatsu, K.   Enomoto, T.  
\n Fujita, M.   Ueda, Y.   Toshihiro Kimura  
\n Kobayashi, E.   Kiyohara, Y.   Tsutsui, T.  
\n Kimura, T.
\n Anticancer Res,  32:4029-4033,  2012 Sep.<\/span>\n <\/p>\n

Prediction of progression-free survival and response to Paclitaxel plus
\n Carboplatin in patients with recurrent or advanced cervical cancer<\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/font><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

Hisamatsu, T.   Mabuchi, S.   Yoshino, K.  
\n Fujita, M.   Enomoto, T.   Hamasaki, T.  
\n Kimura, T.
\n Int J Gynecol Cancer,  22:623-629,  2012 Mar.<\/p>\n<\/p><\/div>\n<\/p><\/div>\n

Chemotherapy for endometrial carcinoma (GOGO-EM1 study) : TEC(paclitaxel,epirubicin,
\n and carboplatin is an effective remission-induction and adjuvant therapy<\/font>
\n <\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span><\/span>Egawa-Takata,T. Ueda, Y. Kuragaki, C. Miyake, T. Miyatake, T.\u3000Fujita, M.
\n Yoshino, K. Nakashima, R. Okazawa, M. Tsutsui, T. Motishige, K. Kimura,
\n T. Yamasaki, M. Nishizaki, T.\u3000Nagamatsu ,M. Ito, K. Asada, M. Ogita, K.
\n Wakimoto, A. Yamamoto, T. Nishino, Y. Enomoto T.<\/span><\/span>
\n Cancer Chemother Pharmacol, 68(6):1603-10, 2011 Dec.
\n <\/o:p>
\n <\/span><\/span>\n <\/p>\n

Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin<\/font>
\n <\/span><\/span><\/span><\/span><\/span><\/span><\/span><\/h3>\n
<\/span><\/p>\n

<\/span><\/span><\/span><\/span><\/span><\/span>Ueno, Y. Enomoto, T. Otsuki, Y. Sugita, N. Nakashima, R. Yoshino, K. Kuragaki,
\n C. Ueda, Y. Aki, T. Ikegami, H. Yamazaki, M. Ito, K. Nagamatsu, M. Nishizaki,
\n T. Asada, M. Kameda, T. Wakimoto, A. Mizutani, T. Yamada, T. Murata, Y.<\/span><\/span>
\n Cancer Lett, 241(6):289-300, 2006 Sep.
\n <\/o:p>
\n <\/span><\/span><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n

\u3053\u306e\u30da\u30fc\u30b8\u306e\u5148\u982d\u3078<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"\u5b66\u4f1a\u767a\u8868 Phase\u2160\/\u2161 trial of glif for taxane\/platinum-resistant endometrial canver Nakagawa, S.   Ueda, Y. […]","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-27","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/wp-json\/wp\/v2\/pages\/27","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/wp-json\/wp\/v2\/comments?post=27"}],"version-history":[{"count":1,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/wp-json\/wp\/v2\/pages\/27\/revisions"}],"predecessor-version":[{"id":146,"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/wp-json\/wp\/v2\/pages\/27\/revisions\/146"}],"wp:attachment":[{"href":"https:\/\/www.med.osaka-u.ac.jp\/pub\/gyne\/osaka-gogo\/wp-json\/wp\/v2\/media?parent=27"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}